RecruitingNot ApplicableNCT06398990

The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea

The Effect of Telerehabilitation-Based Cognitive Exercise Therapy Approach and Yoga on Pain, Physical Function and Quality of Life in Adolescents With Dysmenorrhoea


Sponsor

Acibadem University

Enrollment

42 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Dysmenorrhoea is a condition that negatively affects the quality of life in women of many age groups. In girls with dysmenorrhoea in adolescence, there is an effect on school performance, self-confidence-depression problems and a decrease in quality of life due to pain. In order to eliminate these negative effects, they should receive a good treatment. Medical treatment usually tries to minimise and balance this situation. Considering the fact that families do not want to use drugs such as oral contraceptives in their children at this age and the risks of oral contraceptives, parents are in different searches. Considering that the approach to pain should always be from a holistic perspective, yoga and cognitive exercise therapy approaches are both biopsychosocial treatment methods within the scope of mind-body integrity. Yoga and cognitive exercise therapy approach is thought to reduce symptoms, improve physical functions and quality of life in adolescent girls. With these positive effects, school absenteeism decreases, depression and self-confidence improve. Health costs will also be reduced to some extent.


Eligibility

Sex: FEMALEMin Age: 10 YearsMax Age: 19 Years

Inclusion Criteria7

  • Between the ages of 10 and 19,
  • Having had a menstrual cycle for at least 6-12 months (ACOG, 2018),
  • Having menstrual pain intensity of ≥4 cm according to the Visual Analog Scale (VAS, 0-10 cm) (Kannan, P. 2015; Yonglitthipagon, P. 2017),
  • To have been diagnosed with primary dysmenorrhea according to the clinical characteristics and diagnostic approach defined in international dysmenorrhea guidelines (ACOG 2018; JOGC 2017),
  • Nulliparous (having never given birth),
  • Able to read and write in Turkish,
  • Willing to participate in the study and having provided informed consent.

Exclusion Criteria7

  • History or clinical findings suggestive of secondary dysmenorrhea,
  • Presence of serious comorbidities, including neurological, cardiovascular, musculoskeletal, psychiatric, gastrointestinal, or autoimmune disorders,
  • History of surgery involving the abdominal, pelvic, or spinal regions within the past 12 months,
  • Current pregnancy or suspected pregnancy,
  • Use of intrauterine devices (IUDs),
  • Current or recent participation in cognitive exercise therapy and/or yoga interventions,
  • Concurrent participation in another clinical study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCognitive Exercise Therapy Approach

It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).

OTHERYoga

It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).

OTHERRoutine Medical Treatment

Assessments of individuals in this group will be made face-to-face in the relevant clinic.


Locations(1)

Acibadem Mehmet Ali Aydinlar University

Istanbul, Ataşehir, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06398990


Related Trials